Balchem Q2 2025 net sales rise 9.1% to $255.5 million; GAAP EPS $1.17 vs $0.98
Balchem reported second-quarter 2025 results for the quarter ended June 30, 2025, with net sales of $255.5 million, up 9.1% from the prior year quarter, and GAAP net earnings of $38.3 million, up 19.4%. All three reporting segments grew sales and earnings from operations, and the company repurchased $33.3 million of common stock during the quarter.
Key points
- Net sales were $255.5 million, up $21.4 million, or 9.1%, from $234.1 million a year earlier.
- GAAP diluted EPS was $1.17 versus $0.98; adjusted EPS was $1.27 versus $1.09.
- Adjusted EBITDA was $69.2 million, up 11.2% from $62.3 million; free cash flow was $40.7 million.
- Share repurchases totaled $33.3 million in the quarter, and the company announced a planned $36 million micro-encapsulation facility in Orange County, NY, subject to county approval.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.